@article{6492218dbf6e49fb9e5299ed73a67c54,
title = "Revising the definition of Alzheimer's disease: A new lexicon",
abstract = "Alzheimer's disease (AD) is classically defined as a dual clinicopathological entity. The recent advances in use of reliable biomarkers of AD that provide in-vivo evidence of the disease has stimulated the development of new research criteria that reconceptualise the diagnosis around both a specific pattern of cognitive changes and structural/biological evidence of Alzheimer's pathology. This new diagnostic framework has stimulated debate about the definition of AD and related conditions. The potential for drugs to intercede in the pathogenic cascade of the disease adds some urgency to this debate. This paper by the International Working Group for New Research Criteria for the Diagnosis of AD aims to advance the scientific discussion by providing broader diagnostic coverage of the AD clinical spectrum and by proposing a common lexicon as a point of reference for the clinical and research communities. The cornerstone of this lexicon is to consider AD solely as a clinical and symptomatic entity that encompasses both predementia and dementia phases.",
author = "Bruno Dubois and Feldman, {Howard H.} and Claudia Jacova and Cummings, {Jeffrey L.} and DeKosky, {Steven T.} and Pascale Barberger-Gateau and Andr{\'e} Delacourte and Giovanni Frisoni and Fox, {Nick C.} and Douglas Galasko and Serge Gauthier and Harald Hampel and Jicha, {Gregory A.} and Kenichi Meguro and John O'Brien and Florence Pasquier and Philippe Robert and Martin Rossor and Steven Salloway and Marie Sarazin and {de Souza}, {Leonardo C.} and Yaakov Stern and Visser, {Pieter J.} and Philip Scheltens",
note = "Funding Information: BD has consulted or served on advisory boards for Bristol-Myers Squibb, Novartis, Roche, Elan, Eli Lilly, Eisai, GE Healthcare, Janssen, and Sanofi-Aventis. His institution has received grants from Novartis, Roche, Eisai, and Sanofi-Aventis. HHF has consulted or served on advisory boards and/or study steering committees for AstraZeneca, Bristol-Myers Squibb, Elan, Janssen, Merck Serono, Lundbeck, Novartis, Neuropharma, Wyeth, Noscira, Servier, Glia Scientific, Eisai, and Pfizer. He has received grants for clinical trials sponsored by Elan Pharmaceuticals and Sanofi Synthelabo and performed at the University of British Columbia (UBC). He has received travel/accommodation covered or reimbursed for CME programmes from the Academy of Health Care Education, Alpha Plus, Cadmus Media, Janssen Pharma, Lundbeck, Eisai, AstraZeneca, Pfizer, Medical Decision Point, Informed Direct PLC, Med Plan Communications, and Novartis. He has held stock in Biomarin. From Jan 1, 2009, he has been on leave from UBC and is a full-time employee of Bristol-Myers Squibb. JLC has provided consultation to Abbott, Acadia, Accera, ADAMAS, Astellas, Avanir, Bristol-Myers Squibb, CoMentis, Eisai, Elan, EnVivo, Forest, GlaxoSmithKline, Janssen, Lilly, Lundbeck, Medivation, Merck, Merz, Myriad, Neuren, Neurokos, Novartis, Noven, Orion, Pfizer, Prana, reMYND, Schering Plough, Signum Bioscience, Sonexa, Takeda, Toyama, and Wyeth pharmaceutical companies, and to Bayer, MedAvante, Neurotrax, and UCB. He holds stock in ADAMAS, Prana, Sonexa, MedAvante, Neurotrax, and Neurokos. He has been a speaker/lecturer for Eisai, Forest, Janssen, Novartis, Pfizer, Lundbeck, and Merz, owns the copyright of the Neuropsychiatric Inventory, and has provided expert witness consultation regarding olanzapine and ropinerol. STDK has collaborated with the American Board of Psychiatry and Neurology, Bristol-Myers Squibb, and the University of Virginia School of Medicine. PB-G has no personal conflicts of interest; her institution has received grants from Novartis, Beaufour Ipsen Pharma, Scor Global Life, Danone, and Lesieur. GF has no personal conflicts of interest; his institution has received a grant from the Alzheimer's Association. NCF has served on advisory boards for the Alzheimer's Research Forum and GE Healthcare. His institution has received remuneration, honoraria, and trial support from Abbott, the American Neurological Association, Lundbeck, GE Healthcare, GlaxoSmithKline, Elan Pharmaceuticals, Eli Lilly, Lundbeck, Eisai, IXICO, Pfizer, Janssen, the Movement Disorders Society, Wyeth Pharmaceuticals, Sanofi-Aventis, and Coalition Against Major Diseases Consortium as a result of his consultancy and advisory work. DG has served on the data safety monitoring board for a clinical trial for Jansen Pharmaceutical. GAJ has collaborated with Medivation, Martek Biosciences, and Avanir. JO'B has received honoraria for non-promotional talks and travel/accommodation expenses from Pfizer, Eisai, Shire, Novartis, and Lundbeck, and his institute has undertaken consultancy work for GE Healthcare and Bayer Healthcare. FP has collaborated with Bayer Healthcare; her institution has received grants and honoraria from Servier, Bioprojet, Lundbeck, Eisai, Wyeth, Medivation, Exonhit Therapeutics, and Bristol-Myers Squibb. PR has collaborated with Lundbeck, Merck, Novartis, Janssen-Cilag, and Eisai. MR has served on a safety monitoring committee for Elan Pharmaceuticals, and is Director of the UK Dementia and Neurodegenerative Diseases Clinical Research Network. MS has collaborated with Eisai, Pfizer, Lundbeck, and Servier. LCdS has collaborated with Lundbeck. YS has collaborated with or consulted for Allergan, Cephalon, Elan, Eisai, Pfizer, Ortho-McNeil Neurologics, Merck & Co, GlaxoSmithKline, Eli Lilly, and Janssen-Cilag. PJV has served on advisory boards for Bristol-Myers Squibb, Myriad, Elan-Wyeth, and Ipsen, and has consulted for Danone. His institution has received grants and honoraria from Bristol-Myers Squibb, Diagenic, Novartis, and Lundbeck. PS reports no personal conflict of interest; his institution has received grants from Wyeth, Elan, Genentech, Danone, Novartis, and Janssen-Cilag. CJ has participated in a scientific advisory board meeting organised by Bristol-Myers Squibb. AD, SG, HH, KM, and SS report no conflicts of interest. BD, HHF, NCF, and STDK have been involved in the working group of the American Association for the Revision of the NINCDS–ADRDA criteria for Alzheimer's disease. ",
year = "2010",
month = nov,
doi = "10.1016/S1474-4422(10)70223-4",
language = "English",
volume = "9",
pages = "1118--1127",
journal = "The Lancet Neurology",
issn = "1474-4422",
publisher = "Lancet Publishing Group",
number = "11",
}